An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types Likely to Express Epidermal Growth Factor Receptor (EGFR).

Trial Profile

An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types Likely to Express Epidermal Growth Factor Receptor (EGFR).

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2015

At a glance

  • Drugs Indium 111 ABT 806 (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 16 May 2013 Results will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top